Pfizer decided to discontinue the development of its leading weight management candidate. Despite this setback, the company has a deep pipeline of candidates, especially in oncology. Pfizer's ...

NEW YORK, April 23, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock ...

Pfizer PFE will report its first-quarter earnings on April 29, before market open. The Zacks Consensus Estimate for sales and earnings for the first quarter is pegged at $13.88 billion and 67 ...

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in the Philippines, coinciding with its 175th-year global milestone.

Pfizer is ending the development of its GLP-1 weight loss drug, danuglipron. A patient in a clinical trial experienced a liver injury, potentially due to the drug. Pfizer has a massive pipeline ...

Pfizer on Monday said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient ...

Warren Buffett’s company ended the first quarter with a record $333.3 billion in cash and cash equivalents. Maintaining independence and editorial freedom is essential to our mission of ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...